초록 ▼

A device for delivering a fluid to a patient, including an exit port, a dispenser for causing fluid from a reservoir to flow to the exit port, a local processor programmed to cause a flow of fluid to the exit port based on flow instructions from a separate, remote control device, and a wireless rece

A device for delivering a fluid to a patient, including an exit port, a dispenser for causing fluid from a reservoir to flow to the exit port, a local processor programmed to cause a flow of fluid to the exit port based on flow instructions from a separate, remote control device, and a wireless receiver connected to the local processor for receiving the flow instructions. The device also includes a housing free of user input components for providing flow instructions to the local processor, in order to reduce the complexity and costs of the device so that the device lends itself to being disposable in nature. A system and a kit are also described that include the fluid delivery device, a separate, remote control device, and accessories for transcutaneous delivery of fluid medications. Methods of utilizing the fluid delivery device to infuse fluid medications are additionally disclosed.

대표청구항 ▼

A device for delivering a fluid to a patient, including an exit port, a dispenser for causing fluid from a reservoir to flow to the exit port, a local processor programmed to cause a flow of fluid to the exit port based on flow instructions from a separate, remote control device, and a wireless rece

A device for delivering a fluid to a patient, including an exit port, a dispenser for causing fluid from a reservoir to flow to the exit port, a local processor programmed to cause a flow of fluid to the exit port based on flow instructions from a separate, remote control device, and a wireless receiver connected to the local processor for receiving the flow instructions. The device also includes a housing free of user input components for providing flow instructions to the local processor, in order to reduce the complexity and costs of the device so that the device lends itself to being disposable in nature. A system and a kit are also described that include the fluid delivery device, a separate, remote control device, and accessories for transcutaneous delivery of fluid medications. Methods of utilizing the fluid delivery device to infuse fluid medications are additionally disclosed. ents at desired locations along a flexible support structure and providing a flexible sheath over the entire length forms the sensor array. Measuring the sensor deformation provides an electrical analog of the pressure causing the deformation. Acquiring these measurements in a suitable data acquisition and processing unit, including a display, printing, and plotting capability, completes the hardware elements. Integrated software modules complete the system. g a drug, conducting a procedure, and carrying out a therapy.8. The method of assaying the efficacy of a treatment according to claim 7, wherein the treatment is administering a drug.9. The method of assaying the efficacy of a treatment according to claim 8, wherein the drug is a statin.10. The method of assaying the efficacy of a treatment according to claim 8, wherein the statin is atorvastatin calcium.11. The method of assaying the efficacy of a treatment according to claim 2, wherein the at least three cerebrovascular vessels are arteries.12. The method of assaying the efficacy of a treatment according to claim 11, wherein the arteries are selected from the group of a carotid artery, an internal carotid artery, an external carotid artery, a middle cerebral artery, an anterior cerebral artery, a posterior cerebral artery, an anterior communicating artery, a posterior communicating artery, a vertebral artery, and branches thereof.13. The method of assaying the efficacy of a treatment according to claim 12, wherein the at least three vessels are intracranial vessels.14. The method of assaying the efficacy of a treatment according to claim 1, wherein ultrasound energy is used to collect the data regarding cerebrovascular health status.15. The method of assaying the efficacy of a treatment according to claim 14, wherein a Doppler probe is used to collect the data regarding cerebrovascular health status.16. A method of determining the effects of a treatment on a vessel comprising the application of the method according to claim 1 before and after administration of a treatment.17. The method of determining the effects of a treatment on a vessel according to claim 16, wherein the treatment is administration of a drug.18. The method of determining the effects of a treatment on a vessel according to claim 17, wherein the drug is a vasoactive drug.19. The method of determining the effects of a treatment on a vessel according to claim 17, wherein the drug is suspected of having vascular activity.20. The method of assaying the efficacy of a treatment according to claim 1, wherein the individuals have a vascular disease or a condition that affects vascular function.21. The method of assaying the efficacy of a treatment according to claim 1, wherein the individuals are suspected of having a vascular disease or a condition that affects vascular function.22. The method of assaying the efficacy of a treatment according to claim 1, wherein the individuals are analyzed at a time of normal health and at a time of abnormal health.23. A method of selecting subjects for a clinical trial comprising the steps of: collecting physiological information regarding cerebrovascular health status of a number of individuals being considered as subjects for a clinical trial; correlating the collected physiological information regarding cerebrovascular health status of the individuals being considered for the clinical trial; and selecting subjects for the clinical trial based at least on the correlated physiological information regarding cerebrovascular health; wherein subjects selected for participation in the clinical trial have no more than statistically insignificant variations in cerebrovascular health status; andwherein the data regarding cerebrovascular health status comprises multi-vessel, multi-parameter measurements of cerebral blood flow.24. The method of selecting subjects for a clinical trial according to claim 23, wherein said physiological information regarding cerebrovascular health comprises a mean flow velocity value for at least three cerebrovascular vessels of the individuals and a systolic acceleration value for at least three cerebrovascular vessels of the individuals.25. The method of selecting subjects for a clinical trial according to claim 24, further comprising a pulsatility index value for at least three cerebrovascular vessels of the individuals.26. The method of selecting subjects for a clinical trial according to claim